Loading
Life sciences · Journal article
Extracellular Vesicles and Circulating Nucleic Acids · November 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Antimicrobial resistance (AMR) is a major global health threat that requires innovative approaches to infection prevention and treatment. In 2024, the World Health Organization (WHO) updated its Bacterial Priority Pathogens List (BPPL) to guide research toward the pathogens of highest clinical relevance. Among these, carbapenem-resistant Klebsiella pneumoniae, methicillin-resistant Staphylococcus aureus, and macrolide-resistant Streptococcus pneumoniae remain major contributors to infectious disease burden and AMR-associated mortality worldwide. Recent evidence identifies bacterial extracellular vesicles (bEVs) as important mediators of microbial adaptation, host interaction, and antimicrobial resistance. Released under physiological and stress conditions, bEVs carry proteins, lipids, and nucleic acids that can influence bacterial survival and infection outcomes. In this mini-review, we summarize current knowledge on bEVs produced by these WHO priority pathogens and discuss their emerging roles in infection biology. We highlight how bEVs contribute to antimicrobial resistance through the transport of resistance-associated proteins, the horizontal transfer of resistance genes and antibiotic-degrading activity. We further examine the involvement of bEVs in inflammation, host tissue damage and immune modulation, including their capacity to carry virulence factors or sequester antimicrobial agents. Finally, we discuss recent advances in the use of bEVs as vaccine platforms. We prioritize studies on extracellular vesicles (EVs) from antibiotic-resistant strains of the three WHO priority pathogens. When these were unavailable, we also included studies using antibiotic-susceptible strains, particularly for S. pneumoniae, for which data on macrolide-resistant strains are lacking. Overall, bEVs are increasingly recognized as active components of bacterial physiology and promising targets for developing new strategies against antimicrobial-resistant infections.